Adverse events after Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System, 2024-2025, United States - PubMed
5 hours ago
- #RSV vaccine
- #adverse events
- #pregnancy safety
- The study analyzed adverse events (AEs) reported to the U.S. VAERS for Pfizer's RSV vaccine (Abrysvo) in pregnant women during the 2024-2025 RSV season.
- A total of 131 reports were received; 46 (35%) described injection site and systemic reactions.
- The most common pregnancy-specific outcomes were preterm birth (15 cases, 11%) and hypertensive disorders of pregnancy (9 cases, 7%).
- The reported AEs were consistent with prelicensure studies, supporting the vaccine's safety profile as recommended for pregnant women at 32-36 weeks' gestation.